Figure 6.

The influence of halicin with oral administration (A) (the high-, medium-, and low-dose groups were 25.48, 12.74, and 6.37 mg/kg b.w., respectively) and intraperitoneal injection (B) (the high-, medium-, and low-dose groups were 3.69, 1.47, and 0.74 mg/kg b.w., respectively) on clinical symptom scores in murine respiratory infection with APP S6. The data is represented as mean ± SEM, with six biological replicates per group. One-way ANOVA was used to calculate p-values (* p < 0.05, ** p < 0.01, *** p < 0.001).